Summaries of the Section H (HML) update
Each month we issue a summary of the HML update. The table on this page gives a preview of the upcoming changes.
The table on this page gives a preview of the upcoming changes that will be announced in next month’s Section H of the Pharmaceutical Schedule.
The changes will be published in the Online HML(external link) around the 23rd of this month and are effective from next month.
For any questions about these listing changes or the Pharmaceutical Schedule in general, email us at enquiry@pharmac.govt.nz.
18 February 2025 - preview of changes for March 2025
|
Pharmaceutical |
Change |
|---|---|
|
Acetylcysteine (Martindale Pharma) inj 200 mg per ml, 10 ml ampoule |
delisting delayed to 1 November 2025 |
|
Amino acid formula (without phenylalanine) (PKU Anamix Junior LQ (Unflavoured)) liquid 8 g protein, 7 g carbohydrate, 3.8 g fat and 0.25 g fibre per 100 ml, bottle, 125 ml |
delisted 1 March 2025 |
|
Antithymocyte globulin (Equine) (ATGAM) inj 50 mg per ml, 5 ml ampoule |
price increase |
|
Atazanavir sulphate (Atazanavir Viatris) cap 150 mg |
new listing (p’code 2660016) |
|
Atezolizumab (Tecentriq) inj 60 mg per ml, 20 ml vial |
amended restriction criteria |
|
Atorvastatin (Lipitor) tab 20 mg |
new listing (p’code 2699621) |
|
Benzathine benzylpenicillin (Bicllin LA) inj 900 mg (1.2 million units) in 2.3 ml syringe |
price increase |
|
Bevacizumab (Ocular) inj 25 mg per ml, 4 ml vial and inj 25 mg per ml, 16 ml vial |
amended chemical name |
|
Bevacizumab (Vegzelma) inj 25 mg per ml, 4 ml vial and inj 25 mg per ml, 16 ml vial |
new listing
|
|
Clarithromycin (Klaricid) tab 250 mg |
new listing (p’code 2698056) |
|
Clozapine (Versacloz) oral liq 50 mg per ml, 100 ml |
price increase |
|
Cilazapril (Zapril) tab 0.5 mg, tab 2.5 mg and tab 5 mg |
to be delisted 1 April 2025 |
|
Codeine phosphate (Aspen) tab 30 mg |
delisted 1 March 2025 |
|
Colistin Sulphomethate [Colestimethate] (Colomycin) inj 2 million iu, 10 ml vial |
new listing (p’code 2698005) |
|
Dantrolene (Dantrium) cap 25 mg and (Dantrium IV) inj 20 mg vial |
price increase |
|
Denosumab (Prolia) inj 60 mg prefilled syringe |
price decrease and amended presentation description |
|
Denosumab (Xgeva) inj 120 mg per 1.7 ml vial and (Prolia) inj 60 mg prefilled syringe |
amended restriction criteria |
|
Desferrioxamine mesilate (DBL Desferrioxamine Mesylate for Inj BP) inj 500 mg vial |
price increase |
|
Dulaglutide (Trulicity) inj 1.5 mg per ml, 0.5 ml prefilled pen |
amended note |
|
Emtricitabine with tenofovir disoproxil (Teva) tab 200 mg with tenofovir disoproxil 245 mg (300.6 mg as a succinate) |
to be delisted 1 August 2025 |
|
Entacapone (Entacapone Viatris) tab 200 mg |
brand name change |
|
Flucloxacillin cap 250 mg and cap 500 mg |
Brand change Staphlex – new listing and addition of PSS
Flucloxacillin-AFT to be delisted 1 August 2025 |
|
Gentamicin sulphate (Gentamicin Andipharm) inj 40 mg per ml, 2 ml ampoule |
new listing (p’code 2700506) |
|
Influenza vaccine inj 60 mcg in 0.5 ml |
new listing
Influvac Tetra (2024 formulation) delisted 1 March 2025 |
|
Interferon beta-1-alpha (Avonex Pen) injection 6 million iu per 0.5 ml pen injector |
to be delisted 1 September 2025 |
|
Ketamine (Ketamine-Baxter) inj 100 mg per ml, 2 ml vial |
new listing (p’code 2699915) |
|
Lanreotide (Mytolac) inj 60 mg and 120 mg per 0.5 ml, 0.5 ml syringe |
new listing and addition of PSS
|
|
Lenvatinib (Lenvima) cap 4 mg and 10 mg |
amended restriction criteria |
|
Letrozole (Accord) tab 2.5 mg |
new listing (p’code 2699923) |
|
Levonorgestrel (Microlut) tab 30 mcg, 112 tab pack |
new listing (p’code 2591839) |
|
Levonorgestrel (Microlut) tab 30 mcg, 84 tab pack |
to be delisted 1 December 2025 |
|
Liraglutide (Victoza) inj 6 mg per ml, 3 ml prefilled pen |
amended restriction criteria and note |
|
Long-acting Somatostatin Analogues |
new therapeutic subgroup with restriction criteria |
|
Medroxyprogesterone acetate (Depo-Provera) inj 150 mg per ml, 1 ml syringe |
price increase |
|
Methylprednisolone (as sodium succinate) (Solu-Medrol Act-O-Vial) inj 500 mg vial and (Solu-Medrol) inj 1 g vial |
price increase |
|
Mirtazapine (Noumed) tab 30 mg and tab 45 mg, 28 tab pack |
delisted 1 March 2025 |
|
Molnupiravir (Lagevrio) cap 200 mg |
delisted 1 March 2025 |
|
Naltrexone hydrochloride (Revia) tab 50 mg |
to be delisted 1 July 2025 |
|
Octreotide (Sandostatin LAR) inj depot 10 mg prefilled syringe, inj depot 20 mg prefilled |
depot injections moved to new therapeutic group |
|
Phenylephrine hydrochloride (Neosynephrine HCL) inj 10 mg per ml, 1 ml ampoule |
price increase |
|
Sulfadiazine silver (Ascend) crm 1%, 50 g |
to be delisted 1 July 2025 |
|
Sulfasalazine (Salazopyrin) tab 500 mg and (Salazopyrin EN) tab EC 500 mg |
price increase |
|
Theophylline (Nuelin-SR) tab long-acting 250 mg and (Nuelin) oral liq 80 mg per 15 ml, 500 ml |
price increase |
|
Tixagevimab with cilgavimab (Evusheld) inj 100 mg per ml, 1.5 ml vial and cilgavimab 100 mg per ml, 1.5 ml vial |
delisted 1 March 2025 |
|
Trimethoprim with sulphamethoxazole [co-trimoxazole] (Deprim) oral liq 8 mg with sulphamethoxazole 40 mg per ml, 100 ml |
price decrease and addition of PSS |
|
Venlafaxine (Enlafax XR) cap 75 mg and cap 150 mg, 28 pack |
new listing
|
|
Voriconazole (Vttack) tab 50 mg and tab 200 mg |
price decrease and addition of PSS |